Magazine Article | April 1, 2022

A Q&A With A Venture Capitalist/Genetic Medicines Executive

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

Sung You, managing partner at PBM Capital and chief business and strategy officer at SalioGen Therapeutics, a preclinical genetics medicines company, knows the importance of telling a good story. Formerly a VP at Morgan Stanley’s healthcare investment banking group, You reviews some 1,000 company fundraising proposals each year for PBM Capital, a “stage-agnostic” VC firm that benefits, says You, from not putting external investment dollars on the line. PBM Capital funding comes exclusively from internal resources and can range from as little as $500,000 in initial investment funds, to more than $30 million. By eschewing outside investors, PBM Capital can jump in earlier and take bigger risks.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: